• FDA approves Opdivo for esophageal, gastroesophageal junction cancers

    29 days ago - By Healio

    The FDA approved nivolumab as adjuvant treatment for certain patients with completely resected esophageal or gastroesophageal junction cancers, according to the agent's manufacturer.
    The approval applies to use of the agent by patients who have residual pathologic disease after neoadjuvant chemoradiotherapy and complete resection.
    Nivolumab , a PD-1 inhibitor, is the first immunotherapy approved for this patient population.
    The FDA based the approval on results of the randomized phase 3 CheckMate-577 trial, which included 794 patients with esophageal or
    Read more ...

     

  • Adjuvant Opdivo OK'd for Esophageal, GEJ Cancers

    Adjuvant Opdivo OK'd for Esophageal, GEJ Cancers

    29 days ago - By MedPageToday

    FDA added another indication for nivolumab on Thursday, with the PD-1 immune checkpoint inhibitor now approved as an adjuvant treatment for esophageal and gastroesophageal junction cancers.
    Nivolumab is specifically...
    Read more ...

     

  • FDA OKs Nivolumab After Surgery for Esophageal or GEJ Cancer

    FDA OKs Nivolumab After Surgery for Esophageal or GEJ Cancer

    29 days ago - By Medscape

    The adjuvant use of nivolumab has been described as practice-changing in patients with resected esophageal or gastroesophageal junction cancer who have received chemoradiotherapy before surgery.
    FDA Approvals
    Read more ...